Member Info for OAPK20

Green - China is 30million tests per year at £100 per test.

"This agreement represents a significant opportunity to bring early and cost-effective cancer detection to the people of China. It is estimated that about 95.8 million people in China have a high risk of lung cancer and if screening was performed every three years, then more than 30 million tests per year would be required. At a target price of about GBP100 per test, the total available market for tests based on the CIZ1B biomarker would be GBP3 billion. (Frost & Sullivan estimates the market size in China is US$5.7 billion). We have already secured strong interest from our nationwide network of national clinical centers and key opinion leaders because of the promising results using the CIZ1B biomarker for lung cancer early detection in the UK and one our first tasks is to commence pilot studies at the Cancer Hospital, Chinese Academy of Medical Sciences, National Cancer Centre, and Beijing Cancer Hospital, affiliated with Peking University."

Once US validation comes next step Insurance industry approval would be a big driver

22nd August
Trials agreement signed with Agrii UK

Plant Health Care(R) (AIM: PHC.L ), a leading provider of novel, patent-protected biological products to global agriculture markets, announces a trials agreement with Agrii UK ("Agrii") under which Agrii will evaluate Plant Health Care's novel PREtec technology.

“ The mutual recognition mechanism will help expand the use of Harpin ß in other European countries. Europe is the world's largest market for sustainable agriculture with annual sales of over $2 billion.”

“ new distribution agreement with EDAF Unipessoal LDA for Portugal ”

Have they tickled all the boxes to get the validations underway? Patience.

Hope MURF don’t bank with SVB.

Hi Tom
My understanding is this has been years in the making . CIZ updated in July 22 re
Highlights

-- Monoclonal antibody ("mAb") to CIZ1B now in assay optimisation
-- mAb reporter protein developed and ready for test development
-- mAb supplier agreements extended to increase use case diversity
-- Work initiated to extend use case to breast cancer

Then Sept 22 updates so time is marching on

Continued development of the test reagents, manufacture of test reagents, and validation of test configuration on patient samples

-- Development of a LDT certified test in accredited partner laboratories such as CorePath Laboratories, USA

-- Production of a UKCA, CE marked and/or FDA 510(k) cleared product, following successful validation on retrospective clinical sample sets and control cohorts

-- Market launch and preparation for a clinical trial to support NHS and other global healthcare providers

All of the above could land at anytime.

3.1 support would be nice to see a bounce

Needs news to keep this Hopium rise afloat

On March 7, 2023, Murphy Canyon Acquisition Corp., a Delaware corporation (“Murphy” or the “Company”), issued a promissory note (the “Note”) in the principal amount of up to $1,500,000 to Murphy Canyon Acquisition Sponsor, LLC, the sponsor of the Company (the “Sponsor”), in connection with the extension of the termination date for the Company’s initial business combination (the “Initial Business Combination”) from February 7, 2023, to February 7, 2024, on a month-to-month basis, at the Company’s election. The Note bears no interest and is repayable in full upon the earlier of (i) the date on which the Company consummates its Initial Business Combination and (ii) the date that the winding up of the Company is effective.

Pursuant to the Note, on March 7, 2023 the Sponsor loaned the Company $300,000 to fund its trust account and pay for operating expenses.

The foregoing description is qualified in its entirety by reference to the Note, which is attached as Exhibit 10.1 hereto and is incorporated herein by reference.

News is definitely needed here.

As for PHC DYOR

Have a look at ITS to see these scumbags at work. Look on Twitter before they delete the tweets and remember the account user names.

First they talk about placings, dilution, then put a negative spin on any announcement or anything they think they can dig up, then the personal attacks.
They are late to the price movement and probably don't even hold.

Good luck. Especially yo the long term holders and those who were pre CIZ holders. Hopefully it'll end in decent profits for you. I'll be tucking mine away to wait for validation and commercialisation. Like the CEO said 'You are lucky to be part of this'

Ok.

Going to be interesting

Gutted

I know. I tried to make the point it’s not like some of the pump n dump aim co’s, but not very well

This is a game changing company with a test for the early detection of lung cancer. Not your typical aim oily or mining lifestyle co pumping placings to fund director salaries.
MM played a blinder dropping this and isn’t it funny how all the negative posters from clueless posters suddenly appeared.

Hope nobody had their pockets picked.